Cereno Scientific is granted Expanded Access by the FDA to drug candidate CS1 for rare disease pulmonary arterial hypertension
Cereno Scientific , a company developing innovative treatments for common and rare cardiovascular disease, today announced that the company has been granted approval by the FDA for Expanded Access,...
United States Vastra Gotalands Lan Kendall Square Raymond Benza Cereno Expanded Access Program Ir Communications
Source: marketscreener.com